ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of i…
$13.68+3.32%
报价 2026-11-13
市值
$3.03B
EV
$3.04B
PE (TTM)
16.7x
预期 PE (FY2026)
16.7x
52 周区间距高点 -32.9%
$7.60$20.38
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | $3.03B | +3.3% | +4.7% | 68.5% | 16.7x | 12.0x | 22.3x | |
| PRAXPraxis Precision Medicines, Inc. | $9.17B | +1.0% | +133.3% | 0% | – | – | – | |
| BLTEBelite Bio, Inc | $6.62B | -3.3% | – | 0% | – | – | – | |
| LGNDLigand Pharmaceuticals, Inc. | $6.18B | -2.4% | +10.6% | 97.5% | 31.8x | 21.8x | 68.2x | |
| MIRMMirum Pharmaceuticals, Inc. | $6.14B | +0.7% | +38.9% | 81.7% | – | – | – | |
| ACADACADIA Pharmaceuticals Inc. | $3.24B | +3.4% | +18.4% | 90.5% | 8.6x | 19.5x | 28.4x | |
| DYNDyne Therapeutics, Inc. | $3.22B | +0.9% | +42.9% | 0% | – | – | – | |
| TLXTelix Pharmaceuticals Limited | $3.14B | -1.4% | – | 50.8% | – | 129.6x | – | |
| RAREUltragenyx Pharmaceutical Inc. | $1.64B | -1.2% | +12.9% | 83.1% | – | – | – | |
| 同行中位数 | – | – | +28.6% | 66.2% | 20.2x | 21.8x | 48.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。